The next debate on embryo science
By Editorial,
Nature Biotechnology
| 08. 02. 2021
The International Society for Stem Cell Research has called for broad public dialogue on the ethics of human embryo research beyond 14 days post-fertilization. National jurisdictions should seize the moment.
A longstanding prohibition against culturing human embryos for more than 14 days is now open for discussion, according to revised research guidelines released in May by the International Society for Stem Cell Research (ISSCR). The society’s change in position was prompted by recent advances in embryo culture methods that promise to deepen understanding of human development at the stage when the embryo implants in the uterus—knowledge that may lead to new therapies for infertility and miscarriage. The ISSCR is to be commended for encouraging ethical reflection on extending the 14-day rule before the world is caught off guard by an embryo experiment that goes beyond the accepted time frame. It is now up to interested parties in national scientific, political, ethics and religious communities to take up the ISSCR’s challenge.
In 1978, the birth of the first baby created through in vitro fertilization (IVF) was met with a storm of controversy. IVF provoked deep concerns and anxieties about the wisdom of tampering with the natural order of reproduction. Once human procreation was unlinked from coitus, impossible things became possible: women...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...